Springer Amends Tectonic Therapeutic 13D Filing

TL;DR

Springer updated his Tectonic Therapeutic stake. Watch for more.

AI Summary

On October 24, 2024, Timothy A. Springer filed Amendment No. 2 to Schedule 13D for Tectonic Therapeutic, Inc. This filing indicates a change in beneficial ownership of the company's common stock. The filing does not specify dollar amounts or exact percentages of ownership changes.

Why It Matters

Schedule 13D filings are crucial for investors as they disclose significant changes in ownership of public companies, impacting stock price and corporate control.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can signal shifts in control or strategy, potentially affecting the company's stock performance.

Key Players & Entities

• Tectonic Therapeutic, Inc. (company) — Subject company
• Timothy A. Springer (person) — Filing person
• Michael K. Bradshaw, Jr. (person) — Authorized to receive notices
• Nelson Mullins Riley & Scarborough LLP (company) — Legal counsel

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
• $33.59 — hares from Atlas at a purchase price of $33.59 per share, or $10,077,000 in the aggreg
• $10,077,000 — purchase price of $33.59 per share, or $10,077,000 in the aggregate, payable in cash. Dr.

Filing Documents

• ea0218526-13da2springer_tect.htm (SC 13D/A) — 65KB
• 0001213900-24-090440.txt ( ) — 66KB

of the Schedule 13D is hereby amended to be supplemented by

Item 3 of the Schedule 13D is hereby amended to be supplemented by the following: On October 22, 2024, Dr. Springer entered into a Stock Purchase Agreement with Atlas Venture Fund X, L.P. (“Atlas”), pursuant to which Dr. Springer purchased 300,000 Shares from Atlas at a purchase price of $33.59 per share, or $10,077,000 in the aggregate, payable in cash. Dr. Springer represented that he was an “accredited investor,” as defined in Regulation D, and was acquiring such Shares for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The closing occurred on October 24, 2024. The foregoing summary of the Stock Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Stock Purchase Agreement, a copy of which is filed as Exhibit 99.6 to this Schedule 13D. CUSIP No . 878972108 13D Page 6 of 7 Pages Item 5. Interest in Securities of the Issuer . The information set forth under Item 3 and the cover pages of this (a) The percentages of beneficial ownership reported in this Item 5, and on each Reporting Person’s cover page to this Schedule 13D, are based on a total of 14,734,479 Shares issued and outstanding as of August 9, 2024, as reported on the Issuer’s Quarterly Report on Form 10-Q, dated August 14, 2024. The number of Shares beneficially owned by each Reporting Person has not changed since the date of event that requires filing of this Statement. The Reporting Persons, in the aggregate, beneficially own 4,593,121 Shares, representing approximately 31.2% of such class of securities. Dr. Springer is the beneficial owner of a total of 4,593,121 Shares, representing approximately 31.2% of the outstanding Shares and consisting of (i) 4,096,764 Shares held directly, (ii) 310,223 Shares held by TAS and (iii) 186,134 Shares held by Dr. Lu.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: October 24, 2024 /s/ Timothy A. Springer Timothy A Springer /s/ Chafen Lu Chafen Lu TAS Partners LLC By: /s/ Timothy A. Springer Name: Timothy A. Springer Title: Manager

View Full Filing

View this SC 13D/A filing on SEC EDGAR